Generate:Biomedicines

The generative model is the origin of the molecules rather than a filter applied to them. Chroma samples novel protein structures and sequences directly and can be conditioned toward desired properties, which the company uses to design therapeutics that do not begin from a natural antibody scaffold, and the lead clinical asset GB-0895 is stated to have been developed using the platform's binding affinity and developability optimisation modules. The extensive biohardware, covering DNA assembly, protein production, multiplexed assays and an in house cryogenic electron microscopy core, exists to measure candidates at scale and feed structural data back into the next cycle of model learning. The dependency runs the right way for this grade: the laboratory serves the model.

Oversight is empirical and industrial in scale. The platform is described as a continuous generate, build, measure and learn loop in which billions of molecules are measured through biohardware and structural data is generated to correct the next round of model hypotheses, so designs meet physical evidence continuously rather than accumulating unchecked, with the cryo-EM core producing over 500 high resolution maps in 2025 as one concrete measure of that verification capacity. Held at B because no confidence thresholds, published failure rates or documented human approval gates between model output and programme commitment were located, so the check is architectural rather than specified.

The strongest transparency posture in this category and the direct counter example to the closed end of it. Chroma was published in Nature in November 2023 with a named author list, and the company released the code as open source software with model weights made freely accessible to academic researchers and non profit entities, stating the goal of accelerating progress in generative biology. That means outside researchers can run the model, probe where it fails and contest the claims, which is the condition this index treats as the difference between a demonstrated capability and an asserted one. Platform architecture beyond Chroma is also described concretely, as three modular capabilities covering programmable binding, programmable function, and programmable composition and developability, with the specific modules used for the lead asset identified.

The most advanced clinical position in this category alongside Insilico Medicine, and the evidence is checkable through securities filings rather than press releases alone. GB-0895, a long acting anti TSLP monoclonal antibody engineered for potential every six month dosing, entered global Phase 3 studies for severe asthma with the first Phase 3 patient dosed on 26 January 2026, and is separately in Phase 1b for COPD; GB-4362 received FDA Fast Track designation on 23 January 2026. Partner validation comes from collaborations with Amgen and Novartis. The company also discloses operating specifics most peers do not, including 312 employees as of 31 December 2025 of whom 138 hold MDs or PhDs. Buyers should hold two caveats: no approval exists and Phase 3 entry is not efficacy, and the platform economics claims, reaching proof of concept in three to five years at roughly 25 to 60 million dollars against traditional benchmarks of six to eight years and roughly 380 million, are company generated projections rather than realized results.

Not applicable in the provider sense and rated accordingly rather than penalized. The platform operates on protein structures, sequences and assay and structural data generated in house, with no patient records in the discovery workflow. Human subject protection in the ongoing Phase 3 and Phase 1b studies is governed by trial protocol and site institutional review board oversight rather than by vendor PHI policy.

Not applicable. The company is a clinical stage therapeutics developer and research collaborator rather than a business associate of covered entities handling protected health information.

No SOC 2, ISO 27001 or equivalent attestation was located and no trust center was found. As a Nasdaq registrant the company is subject to disclosure controls and cybersecurity risk reporting obligations, which is an indirect assurance mechanism rather than a security attestation, and the two should not be conflated during diligence.

The strongest regulatory standing in this category alongside Insilico Medicine, and correctly structured, with the platform not presented as a regulated device and regulatory activity at the asset level. GB-0895 is in global Phase 3 for severe asthma with dosing underway and in Phase 1b for COPD, and GB-4362 received FDA Fast Track designation on 23 January 2026. Buyers should note the standard qualifications that Fast Track is a development and review process mechanism rather than an approval or a finding of efficacy, and that no product has been approved.

No formal AI governance framework or bias disclosure was located, though the open release of Chroma is itself governance relevant in a way the company does not frame as such: publishing code and weights lets external researchers characterize where the model degrades, which is the capability the closed platforms in this category deny their own buyers. Two questions remain open. The domain relevant bias question is that a model learning from the Protein Data Bank inherits that archive's structural coverage, so performance will be uneven across protein families that are poorly represented in solved structures, and no breakdown by family or data density was located. Separately, open release of a general purpose de novo protein design capability carries dual use considerations that are an active subject of scientific policy discussion, and no accompanying release governance or access policy addressing them was identified in the materials reviewed.

Not applicable. This is a discovery and clinical development organization with no provider workflow surface and no EHR touchpoint.

Not applicable in the software sense. The Generate Platform is operated internally and coupled to the company's own biohardware and cryo-EM infrastructure rather than deployed to customers, and the commercial relationship is collaboration rather than licensing, so tenancy and residency questions do not arise for a counterparty. The exception is Chroma itself, which is distributed publicly as open source with weights available to academic and non profit users, meaning that component runs wherever the user chooses to run it.

Public listing forces the disclosure and the company met it in detail. An S-1 was filed on 4 February 2026 ahead of a Nasdaq debut on 27 February 2026 under the ticker GENB, priced at 16 dollars per share for 25 million shares raising roughly 400 million dollars gross, with a 30 day overallotment option for up to 3,750,000 additional shares that would take gross proceeds to roughly 460 million. Filings disclose programme by programme status, headcount and composition, platform throughput figures and stated use of proceeds covering the Phase 3 programme, other pipeline assets and platform investment. The unflattering half is also on the record: shares opened at 15 dollars, below the offering price. No rate card exists and none would apply, since the commercial surface is the pipeline plus collaborations with Amgen and Novartis.

Broad within one modality class and absent outside it. The platform addresses protein therapeutics across antibodies, bispecifics, cytokines and entirely new protein modalities that do not derive from natural scaffolds, with a disclosed pipeline spanning respiratory disease, oncology and immunology. Small molecules are out of scope entirely, which is the real boundary. Buyers should note the concentration risk that the company's clinical credibility currently rests heavily on a single asset, GB-0895, in severe asthma and COPD.